Persistence of derivative chromosome 22 after achieving a major molecular response in chronic myeloid leukemia with a cryptic BCR-ABL1 fusion gene
- PMID: 19998064
- DOI: 10.1007/s12185-009-0448-5
Persistence of derivative chromosome 22 after achieving a major molecular response in chronic myeloid leukemia with a cryptic BCR-ABL1 fusion gene
Abstract
We herein report the findings of a 47-year-old Japanese female with chronic myeloid leukemia (CML) with a cryptic BCR-ABL1 transcript on chromosome 9 and a derivative chromosome 22 unrelated to BCR-ABL1. Although she achieved and continued to demonstrate a major molecular response to imatinib treatment following interferon-alpha, there was persistence of a derivative chromosome 22. A detailed chromosome/molecular studies, including serial karyotyping analysis, finally resulted in the karyotyping at the disease onset to be 47,XX,+del(22)(q11.2), with two genetic evens, namely a cryptic BCR-ABL1 transcript on chromosome 9 and derivative chromosome 22 unrelated to BCR-ABL1. This CML case with these two rare genetic events thus raises diagnostic issues such as the difficulty in making a concise evaluation of the chromosomal/molecular events and an accurate disease prognosis, as well as the difficulty in determining the disease remission status after treatment.
Similar articles
-
Heterogenic molecular basis for loss of ABL1-BCR transcription: deletions in der(9)t(9;22) and variants of standard t(9;22) in BCR-ABL1-positive chronic myeloid leukemia.Genes Chromosomes Cancer. 2002 Jun;34(2):193-200. doi: 10.1002/gcc.10056. Genes Chromosomes Cancer. 2002. PMID: 11979553
-
BCR-ABL1 positive AML or CML in blast crisis? A pediatric case report with inv(3) and t(9;22) in the initial clone.Cancer Genet. 2021 Jun;254-255:70-74. doi: 10.1016/j.cancergen.2021.02.007. Epub 2021 Feb 19. Cancer Genet. 2021. PMID: 33647814
-
[Chronic myeloid leukemia with variant e19a2 BCR-ABL1 fusion transcript: interest of the molecular identification at diagnosis for minimal residual disease follow-up].Ann Biol Clin (Paris). 2014 May-Jun;72(3):359-66. doi: 10.1684/abc.2014.0960. Ann Biol Clin (Paris). 2014. PMID: 24876147 French.
-
Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemia.Am J Hematol. 2009 Aug;84(8):517-22. doi: 10.1002/ajh.21457. Am J Hematol. 2009. PMID: 19544476 Review.
-
Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor.Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S96-S100. doi: 10.1016/j.clml.2016.03.008. Epub 2016 Apr 1. Clin Lymphoma Myeloma Leuk. 2016. PMID: 27131622 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous